Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.
about
Mechanism-Oriented Therapy of Irritable Bowel SyndromeFood, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndromeIntestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?The quest for biomarkers in IBS-where should it lead us?Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoeaBile Acid diarrhea: prevalence, pathogenesis, and therapyReview article: bile acid diarrhoea - pathogenesis, diagnosis and managementThe response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.Irritable bowel syndrome: an integrated explanatory model for clinical practice.Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndromeAre the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea.Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.Advances in IBS 2016: A Review of Current and Emerging Data.Pharmacologic Agents for Chronic Diarrhea.Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.The role of bile acids in functional GI disorders.Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study.Gastrointestinal motility and neurogastroenterology.Underlying molecular and cellular mechanisms in childhood irritable bowel syndromeDrug discovery approaches to irritable bowel syndrome.Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis.New and Investigational Agents for Irritable Bowel Syndrome.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.Common Functional Gastroenterological Disorders Associated With Abdominal Pain.Bile acid disease: the emerging epidemic.More similarities than differences between men and women with irritable bowel syndrome.New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.Interplay between bile acid metabolism and microbiota in irritable bowel syndrome.Pharmacotherapy for Irritable Bowel Syndrome.Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.Editorial: diagnosing bile acid diarrhoea with blood tests.Editorial: developing a stimulation test to identify FGF19 deficiency in bile acid diarrhoea.Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.Existing and emerging therapies for managing constipation and diarrhea.Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Irritable bowel syndrome
P2860
Q26747875-801B8ACB-48C4-4F43-BB88-0EB270D15B62Q26777388-33183CED-B292-46F7-981D-5EDA87E751BDQ26828617-08C43769-5780-4DD2-A9FA-8EC8C366D41BQ27024239-90FEB843-26D2-4D34-A1BB-08C2139D0D99Q28081213-B56079D0-C147-426C-9D6C-2068AEC744D2Q28086845-299B16C7-9BB9-4970-9BE2-9423A7251642Q28273649-244B6551-7C9D-4E56-8014-C20FA43B5E6FQ34444158-6E036829-DEBA-4BCA-8274-7D28855CC969Q35565145-0CFCE0E4-9C41-4114-915B-297A357BD37BQ35825711-C0657BB5-80E2-4739-9D67-802E50E90905Q35926089-C9D9FC93-49F0-4FE5-B765-8809FD4FD46EQ36082843-DBFCDFEB-9274-4E63-A956-3799362C91ACQ36245061-C104C53A-D170-43F0-B41A-5883EBDE81C2Q36271715-E4E8608D-4E7E-496F-834E-E4FA6155FDA1Q37632259-07C61302-320F-4C56-90E7-955B8B5C2A76Q38217671-8E5018BF-2C68-4C11-8F02-8F5E6411C75DQ38374046-DCDC5665-A555-4310-83EF-883CA1CB1A51Q38386653-A8BC6397-D6BF-45B1-9AF7-ED9A2DBC91E8Q38515695-013ACC4A-877E-47CA-8DF6-5F3FF1B9657DQ38550878-F328E43F-7116-4216-B017-91C5D07B5547Q38582664-E8CC61DE-3A8D-4EDA-BDFB-361D84F437D0Q38601834-3C90A896-8518-4DE0-8C0D-AAC3CDE7F235Q38630721-734FABF7-2D03-4A12-9FED-A97BF8EB957CQ38687017-85B615B0-ADD2-4B56-9440-2BA4F49CFF49Q38919181-70D62A84-00FF-4E0F-911D-F699FFFA5864Q39124316-C0598E96-47FD-45C4-B60E-57747EC3784CQ41148121-D43FD7B3-4341-499F-A607-D2C998EE506BQ43062026-AF24D51C-8BA8-4913-963B-9CC0C4B4D1F8Q43913058-CB82C4E0-DE26-4A30-B3EE-106B5940E94CQ47117277-FCA92385-CFB8-4244-BCBE-586D8804F823Q47441583-BC28DA0D-7B6A-4615-ADC6-04B1CD5F8057Q48112817-49A6E15C-E614-4423-8585-10B89A83D26AQ48315900-3F989B1E-B035-49A1-961C-B7CD17844DF9Q48389586-EDE33DC3-EA8D-44A8-9BBF-9EB54472906FQ49677641-B191BB2B-3291-4187-952D-C0BAE04E57EAQ50448468-4BF8309B-731C-4442-AC92-7058A6B4DEEBQ50535134-560868A3-993A-4C95-A8FF-D54D1570D751Q56965677-E9581F3E-7B7B-4B38-9178-C93DBF471F9A
P2860
Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Increased colonic bile acid ex ...... symptoms and treatment in IBS.
@en
Increased colonic bile acid ex ...... symptoms and treatment in IBS.
@nl
type
label
Increased colonic bile acid ex ...... symptoms and treatment in IBS.
@en
Increased colonic bile acid ex ...... symptoms and treatment in IBS.
@nl
prefLabel
Increased colonic bile acid ex ...... symptoms and treatment in IBS.
@en
Increased colonic bile acid ex ...... symptoms and treatment in IBS.
@nl
P2093
P2860
P1433
P1476
Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS
@en
P2093
Hans Törnblom
Magnus Simrén
Mats Rudling
P2860
P356
10.1136/GUTJNL-2013-305965
P407
P577
2014-04-12T00:00:00Z